Your browser doesn't support javascript.
loading
Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19.
Kombarova, S Yu; Aleshkin, A V; Novikova, L I; Bochkareva, S S; Zatevalov, A M; Mekhtiev, E R; Mizaeva, T E; Basov, A A; Borisova, O Yu; Likhanskaya, E I; Voropaeva, E A; Urban, Yu N; Mitrokhin, S D; Shkoda, A S; Gushchin, V A; Sinyavin, A E; Nikiforova, M A; Lebedin, Yu S; Karaulov, A V.
Afiliação
  • Kombarova SY; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Aleshkin AV; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Novikova LI; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Bochkareva SS; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Zatevalov AM; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Mekhtiev ER; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Mizaeva TE; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia. toita.mizaeva@bk.ru.
  • Basov AA; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Borisova OY; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Likhanskaya EI; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Voropaeva EA; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Urban YN; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Mitrokhin SD; L. A. Vorokhobov City Clinical Hospital No. 67, Moscow Healthcare Department, Moscow, Russia.
  • Shkoda AS; L. A. Vorokhobov City Clinical Hospital No. 67, Moscow Healthcare Department, Moscow, Russia.
  • Gushchin VA; N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
  • Sinyavin AE; N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
  • Nikiforova MA; N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
  • Lebedin YS; LLC "XEMA", Moscow, Russia.
  • Karaulov AV; G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
Bull Exp Biol Med ; 173(6): 734-739, 2022 Oct.
Article em En | MEDLINE | ID: mdl-36322302
IgM and IgG antibodies to the SARS-CoV-2 virus are detected in subjects who have recovered from COVID-19; IgM antibodies persist in a 1/3 of infected subjects up to 12 months from the moment of the disease, while IgG antibodies are present in the vast majority of cases (97%; medium and high levels antibodies were registered in 85% of cases). By the 12th month, 40% of those who recovered still have a very high level of IgG antibodies to the S-protein (>500 BAU/ml). In the feces, urine, and blood serum of patients with long-term persistent IgM antibodies, no coronavirus antigens were detected. After vaccination with the Gam-COVID-Vac vaccine, IgG antibodies to the S-protein are detected in 100% of cases and remain at a high level for 4 months, by the 5-6th month, the level of antibodies decreases. During revaccination, the level of IgG antibodies to S-protein reaches high values earlier than during primary vaccination, and remains high for 4 months (observation period). The blood sera of recovered and vaccinated patients have a high virus-neutralizing activity (at least 1:80), while its level is somewhat higher in recovered patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Anticorpos Antivirais Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Anticorpos Antivirais Idioma: En Ano de publicação: 2022 Tipo de documento: Article